Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHAGEM: Personalized Interferon-alfa in Membranous Nephropathy
NCT05941845Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2a in membranous nephropathy (MN), sponsored by Centre Hospitalier Universitaire de Nice. Started Sep 2023; status: terminated.
02
Drugs
peginterferon alfa-2a
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT05941845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941845.